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Behavioral/Systems/Cognitive

Augmented Cocaine Seeking in Response to Stress or CRF
Delivered into the Ventral Tegmental Area Following
Long-Access Self-Administration Is Mediated by CRF
Receptor Type 1 But Not CRF Receptor Type 2
Jordan M. Blacktop, Chad Seubert, David A. Baker, Nathan Ferda, Geng Lee, Evan N. Graf, and John R. Mantsch
Department of Biomedical Sciences, Marquette University, Milwaukee, Wisconsin 53201

Stressful events are determinants of relapse in recovering cocaine addicts. Excessive cocaine use may increase susceptibility to stressorinduced relapse through alterations in brain corticotropin-releasing factor (CRF) regulation of neurocircuitry involved in drug seeking.
We previously reported that the reinstatement of cocaine seeking by a stressor (footshock) is CRF dependent and is augmented in rats that
self-administered cocaine under long-access (LgA; 6 h daily) conditions for 14 d when compared with rats provided shorter daily cocaine
access [short access (ShA) rats; 2 h daily]. Further, we have demonstrated that reinstatement in response to intracerebroventricular CRF
administration is heightened in LgA rats. This study examined the role of altered ventral tegmental area (VTA) responsiveness to CRF in
intake-dependent increases in CRF- and stress-induced cocaine seeking. Bilateral intra-VTA administration of CRF (250 or 500 ng/side)
produced reinstatement in LgA but not ShA rats. In LgA rats, intra-VTA CRF-induced reinstatement was blocked by administration of the
CRF-receptor type 1 (CRF-R1) antagonist antalarmin (500 ng/side) or CP-376395 (500 ng/side), but not the CRF-R2 antagonist
astressin-2B (500 ng or 1 g/side) or antisauvagine-30 (ASV-30; 500 ng/side) into the VTA. Likewise, intra-VTA antalarmin, but not
astressin-2B, blocked footshock-induced reinstatement in LgA rats. By contrast, neither intra-VTA antalarmin nor CP-376395 altered
food-reinforced lever pressing. Intra-VTA injection of the CRF-R1-selective agonist cortagine (100 ng/side) but not the CRF-R2-selective
agonist rat urocortin II (rUCN II; 250 ng/side) produced reinstatement. These findings reveal that excessive cocaine use increases
susceptibility to stressor-induced relapse in part by augmenting CRF-R1-dependent regulation of addiction-related neurocircuitry in the VTA.

Introduction
Cocaine addiction is associated with a persistent susceptibility to
drug relapse that emerges in an intake-dependent manner with
repeated use. Understanding the neurobiological mechanisms
that underlie drug relapse in cocaine addicts is critical to the
development of effective treatment. Much evidence suggests that
stress contributes to relapse. Stress promotes craving in abstinent
human cocaine addicts (Sinha et al., 1999) and precipitates reinstatement in rodent relapse models (Erb et al., 1996; Ahmed and
Koob, 1997).
The preclinical study of addiction-related, drug-induced neuroplasticity has involved the use of the long-access selfadministration approach (Ahmed and Koob, 1998) in which rats
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administration (6 –10 h/daily) are compared with rats provided
shorter daily drug access [short access (ShA); 1–2 h/d]. We have
reported that, compared with ShA rats, LgA rats are more susceptible to reinstatement by a stressor, footshock, suggesting that
repeated cocaine use can produce intake-dependent alterations
in how stress regulates neurocircuitry subserving motivation and
relapse susceptibility (Mantsch et al., 2008). Our findings are
consistent with reports that the magnitude of stress-induced
craving is influenced by the amount of prior use in human addicts
(Fox et al., 2005).
The neuropeptide, corticotropin releasing factor (CRF), is a key
mediator of stress-induced cocaine seeking (Shalev et al., 2010). CRF
receptor antagonists block stress-induced reinstatement (Erb et al.,
1998; Shaham et al., 1998; Graf et al., 2011), while delivery of CRF
directly into the brain reinstates cocaine seeking (Erb et al., 2006;
Mantsch et al., 2008). One key site at which CRF promotes reinstatement is the ventral tegmental area (VTA) (Wise and Morales, 2010)
where CRF delivery precipitates reinstatement following selfadministration (Wang et al., 2005, 2007). The VTA receives CRFcontaining projections from a number of brain regions (Rodaros et
al., 2007), and in vivo microdialysis studies have found that, during
footshock-induced reinstatement, VTA extracellular CRF levels are
elevated (Wang et al., 2005).
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Figure 1. A–C, Injection sites within the VTA for the following: LgA rats (triangles), ShA rats (squares), and Sal rats (circles) (A); LgA rats tested for CRF-induced reinstatement following
CP-376395 (triangles), ASV-30 (circles), antalarmin (diamonds), and astressin-2B (squares), or LgA rats tested for footshock-induced reinstatement (stars) (B); and rats tested for effects on
food-reinforced responding (open circles) and LgA rats tested for reinstatement by CRF receptor agonists (closed circles) (C).

Although both CRF-R1 and CRF-R2 subtypes have been reported to be expressed in the VTA, the degree of expression,
cellular localization, and function of these receptors in the VTA is
controversial, and the receptor mechanism through which CRF
regulates cocaine seeking remains unclear. Wang et al. (2005,
2007) have reported that reinstatement by intra-VTA CRF involves an activation of CRF-R2s that relies on an interaction with
CRF binding protein, consistent with the mechanism through
which CRF acutely enhances NMDA receptor-mediated currents
in the VTA (Ungless et al., 2003). However, others have found
that stress-induced reinstatement and evoked increases in VTA
and nucleus accumbens (NAc) dopamine rely on CRF-R1 and
not CRF-R2 (Shaham et al., 1998; Lu et al., 2001, 2003).
We have reported that reinstatement by centrally administered CRF is also augmented following LgA drug selfadministration, suggesting that enhanced CRF responsiveness
contributes to heightened stress-induced relapse (Mantsch et
al., 2008). In this study, we examine intake-dependent augmentation of intra-VTA CRF-induced reinstatement and the
role of VTA CRF-R1 versus CRF-R2 in reinstatement in response to CRF and stress.

Materials and Methods
Adult male Sprague Dawley rats (Harlan Laboratories) were housed individually under a 12 h reversed light/dark cycle (lights on at 7:00 P.M.)
in a temperature and humidity controlled Association for Assessment
and Accreditation of Laboratory Animal Care-accredited animal facility.
All procedures were approved by the Marquette University Institutional
Animal Care and Use Committee and performed in accordance with the
NIH Guide for the Care and Use of Laboratory Animals.
Catheter and cannula implantation. For the reinstatement studies, rats
were implanted with chronic indwelling jugular catheters under ketamine HCl (100 mg/kg, i.p.) and xylazine (2 mg/kg, i.p.) anesthesia, as
previously described (Mantsch et al., 2008; Graf et al., 2011), and with

bilateral 11 mm 26 gauge guide cannulae aimed at the VTA for intracranial injections. The tips of the guide cannulae were aimed 0.5 mm above
the target injection site using the following coordinates determined from
Paxinos and Watson (1998): 12° angle away from midline; anteroposterior ⫺5.6 mm from bregma; mediolateral ⫹2.2 mm from midline; and
dorsoventral ⫺6.7 mm from the skull surface. Placements for cannulae
targeting the VTA for rats from each of the experiments are depicted in
Figure 1.
Self-administration training. After recovery from surgery, rats were
trained to self-administer cocaine (1.0 mg/kg/infusion, i.v.; NIDA Drug
Supply Program) by pressing a lever under a fixed ratio 1 (FR1) schedule
during daily 2 h sessions, within which the active (i.e., front) lever was
extended into the chamber and the corresponding stimulus light was
illuminated. Pressing the lever resulted in an intravenous infusion of
drug or saline (Sal) solution (200 l over 5 s) followed by a 25 s time-out
period during which the stimulus light was extinguished but the lever
remained extended. Responding on a second, inactive (i.e., back) lever
was recorded but had no programmed consequences. Response requirements were gradually increased until rats displayed stable responding
(within 10% of the three session mean) under an FR4 schedule, at which
time they entered into a 14 day period of self-administration testing.
Effects of LgA self-administration on intra-VTA CRF-induced reinstatement. To examine intake-dependent effects of cocaine self-administration on later reinstatement by intra-VTA CRF, rats were assigned to
ShA or LgA groups after self-administration training according to their
access conditions for cocaine self-administration for the next 14 d. ShA
rats (n ⫽ 6) continued to have access to cocaine for 2 h daily, as described
above. LgA rats (n ⫽ 8) had access to the same cocaine dose for 6 h daily.
Additionally, a third group of rats with no history of cocaine selfadministration had access to infusions of saline during 14 daily 2 h sessions and served as a control to examine nonspecific effects of intra-VTA
CRF on lever pressing (n ⫽ 6). Following 14 d of self-administration, rats
underwent extinction during 10 consecutive 2 h sessions within which
the cocaine solution was replaced by saline. After extinction, rats received
a bilateral sham intra-VTA injection before testing for reinstatement in
response to bilateral intra-VTA delivery of CRF (250 or 500 ng/side;
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Sigma-Aldrich) or vehicle (Veh) (0.9% NaCl) delivered in a volume of
0.25 l/side over a 1 min period 10 min before the reinstatement session.
Responding on both the cocaine and inactive levers was recorded during
the 2 h reinstatement sessions, which were otherwise identical to extinction conditions. The order of testing with the two CRF doses and vehicle
varied across rats in each group to avoid potential sequence effects. Rats
underwent additional extinction sessions between reinstatement test sessions and were required to display ⬍20 cocaine lever responses during an
intervening extinction session to be tested again for reinstatement.
Effects of CRF receptor antagonists on intra-VTA CRF-induced reinstatement. To examine the role of CRF-R1 and CRF-R2 in reinstatement by
intra-VTA administration of CRF, the ability of CRF (500 ng/side) to
reinstate cocaine seeking following a 15 min bilateral intra-VTA pretreatment (0.25 l/side over 1 min) with the CRF-R1-selective antagonists
antalarmin (500 ng/side; Sigma Aldrich; n ⫽ 7) (Webster et al., 1996) or
CP-376395 (500 ng/side; Tocris Biosciences; n ⫽ 6) (Chen et al., 2008),
or the CRF-R2-selective antagonists astressin-2B (500 ng and 1 g/side;
Sigma-Aldrich; n ⫽ 6) or antisauvagine-30 (ASV-30; 500 ng/side; SigmaAldrich; n ⫽ 6) was determined in separate groups of LgA rats. The
astressin-2B and ASV-30 doses that were selected were based on those
previously used for intracranial injections (Henry et al., 2006; Forster et
al., 2008). After 14 d of LgA self-administration and extinction, rats were
tested twice for CRF-induced reinstatement in counterbalanced sequence: once following intra-VTA pretreatment with CRF receptor antagonist; and once following pretreatment with vehicle. In the case of the
CRF-R2 antagonist astressin-2B, rats were also treated with a second,
higher antagonist dose (1 g/side).
Effects of CRF receptor antagonists on stress-induced reinstatement. To
examine the role of CRF-R1 and CRF-R2 activation in the VTA in stressinduced reinstatement, separate groups of rats were tested for the ability
of electric footshock, delivered though the stainless steel grid floors of the
self-administration chambers, to reinstate cocaine seeking following bilateral intra-VTA delivery of the CRF-R1-selective antagonist antalarmin
(500 ng/side; n ⫽ 7) or the CRF-R2-selective antagonist astressin-2B (500
ng/side; n ⫽ 8). During the 15 min footshock period, the houselight was
illuminated, the levers were retracted, and stimulus lights extinguished.
Shocks (0.5 mA, 0.5 s duration) were delivered an average of every 40 s
(range, 10 –70 s). We have reported that these parameters produce robust
reinstatement after long-access, but not short-access, self-administration
(Mantsch et al., 2008). As was the case with intra-VTA CRF, rats were
tested twice for footshock-induced reinstatement in counterbalanced
fashion: once following intra-VTA pretreatment with CRF receptor antagonist; and once following pretreatment with vehicle.
Food self-administration. To confirm that the effects of intra-VTA
antalarmin and CP-376395 on reinstatement were not attributable to
nonspecific motor impairments, rats were tested for effects on sucrose
pellet-reinforced lever pressing (data not shown). These rats were maintained at 90% of their free-feeding body weights and were trained to
self-administer 45 mg sucrose-sweetened food pellets (BioServ) by pressing a response lever under an FR4 schedule of reinforcement during 30
min sessions. Once stable response patterns were observed (responding
within 10% of the mean over three sessions), separate groups of rats were
tested for the effects of intra-VTA delivery of antalarmin (500 ng/side;
n ⫽ 10) or CP-376395 (500 ng/side; n ⫽ 6), as described above, on
responding. Each rat was tested twice with intra-VTA treatment in counterbalanced sequence: once with the CRF-R1 antagonist; and once with
vehicle.
Reinstatement by intra-VTA administration of CRF receptor agonist
drugs. To further examine the role of CRF-R1 and CRF-R2 in reinstatement, a separate group of LgA rats (n ⫽ 5) was tested for reinstatement
following bilateral intra-VTA administration of the CRF-R1-selective
agonist cortagine (100 ng/side) (Tezval et al., 2004), the CRF-R2selective agonist rat urocortin II (250 ng/side) (Reyes et al., 2001), or
vehicle (5 mM acetic acid in sterile saline). Following self-administration
and extinction, each rat was tested with each intra-VTA treatment in
counterbalanced sequence. After the first test, rats were only tested again
for reinstatement if they emitted ⬍20 responses during an intervening
extinction session.

Histological confirmation of injection sites. The accuracy of cannula
implantation was confirmed postmortem in each rat after cardiac perfusion with 60 ml of NaCl followed by 60 ml of 2.5% buffered neutral
formalin under sodium barbital anesthesia (55 mg/kg). Brains were removed and stored in 2.5% buffered formalin for at least 1 d. Two hundred micrometer sections were cut using a vibrotome, slide-mounted,
and stained with cresyl violet for placement confirmation using a light
microscope. Rats with injection sites outside of the VTA were excluded
from data analysis. Notably, in cases where the injection sites were outside of the VTA (eight rats), bilateral intracranial delivery of the 500
ng/side CRF dose failed to produce significant reinstatement (mean responses, 20.38 ⫾ 5.51 vs 47.50 ⫾ 7.20 for rats with injection sites within
the VTA).
Statistical analyses. Statistical analyses were conducted using Predictive Analytics SoftWare statistics software (SPSS). Statistical significance
was determined using ANOVA or Student’s t tests followed, when appropriate, by further analyses of main effects using ANOVA and/or post hoc
testing using Bonferroni-corrected t tests.

Results
Effects of self-administration access condition on
reinstatement by intra-VTA CRF self-administration
As expected, escalated self-administration was observed in rats
provided daily long access (6 h; LgA rats, n ⫽ 8) but not short
access (2 h; ShA rats, n ⫽ 6) to cocaine for self-administration
and was not observed in rats provided access to saline (Sal rats,
n ⫽ 6). For analysis, the mean daily hourly self-administration
(infusions per hour) was compared across groups over the 14 d
time period (Fig. 2 A). Two-way ANOVA examining the effects of
self-administration condition (ShA, LgA, and Sal) and day (1–14,
repeated-measures) on the hourly number of self-administered
infusions showed a significant overall main effect of selfadministration condition (F(2,16) ⫽ 23.561; p ⬍ 0.001) but not
day, and a significant condition ⫻ day interaction (F(26,208) ⫽
2.708; p ⬍ 0.01). The daily number of self-administered infusions
increased across the 14 d of self-administration in LgA but not
ShA or Sal rats (one-way ANOVA: F(13,78) ⫽ 2.520; p ⬍ 0.01). Post
hoc testing showed that self-administration was increased in LgA
rats on days 5 and 9 –14 compared with ShA rats (p ⬍ 0.05 for
each comparison, Bonferroni-corrected t test). The mean net cocaine intake over the 14 sessions was markedly higher in LgA rats
compared with ShA rats (t(11) ⫽ 5.889; p ⬍ 0.001) and is shown in
the inset of Figure 2 A.
Extinction and intra-VTA CRF-induced reinstatement
Responding did not differ between ShA and LgA rats during the
10 extinction sessions before reinstatement testing (Fig. 2 B).
However, differences in reinstatement in response to intra-VTA
CRF (250 or 500 ng/side) were observed (Fig. 2C). Reinstatement
by intra-VTA CRF was only observed in rats with a history of LgA
self-administration. Two-way self-administration group (ShA,
LgA, Sal) ⫻ reinstatement condition (Veh: 250 ng/side CRF, 500
ng/side CRF) repeated-measures ANOVA showed significant
main effects of self-administration group (F(2,17) ⫽ 16.774; p ⬍
0.001) and reinstatement condition (F(2,34) ⫽ 7.934; p ⫽ 0.001),
and a significant group ⫻ reinstatement condition interaction
(F(4,34) ⫽ 5.969; p ⫽ 0.001). CRF-induced increases in responding were only found in rats with a history of LgA selfadministration (one-way repeated-measures ANOVA; F(2,14) ⫽
10.639; p ⬍ 0.01). Post hoc testing showed that responding
following intra-VTA administration of the 500 ng/side CRF dose
was significantly increased compared with vehicle (p ⬍ 0.05).
Additionally, responding on the previously active lever was significantly increased in LgA rats compared with ShA and Sal rats
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ment, and significant interactions between
CRF-R1 antagonist pretreatment and CRFinduced reinstatement (F(1,6) ⫽ 5.696, p ⫽
0.05 for antalarmin; F(1,5) ⫽ 9.120, p ⬍ 0.05
for CP-376395). Intra-VTA CRF produced
significant reinstatement following pretreatment with vehicle (p ⬍ 0.01 for each
experiment), but not antalarmin or CP376395, and responding following intraVTA CRF administration was significantly
lower following antalarmin or CP-376395
pretreatment compared with vehicle pretreatment (p ⬍ 0.01).

Figure 2. Self-administration, extinction, and reinstatement of cocaine seeking by intra-VTA injections of CRF in ShA (14 ⫻ 2
h/d) and LgA (14 ⫻ 6 h/d) rats and in saline self-administration control rats. A, Data represent the daily mean hourly numbers of
self-administered infusions (⫾SE) in ShA, LgA, and Sal rats across the 14 day test period. Escalation was observed in LgA, but not
ShA or Sal rats (**p ⬍ 0.05 overall effect), and self-administration was increased in LgA rats compared with ShA (and Sal) rats on
days 5 and 9 –14 of self-administration (*p ⬍ 0.05). The cumulative total cocaine intake (in milligrams per kilogram ⫾ SE) in ShA
and LgA rats is shown in the inset in A. Intake was markedly and significantly increased in LgA rats (**p ⬍ 0.001 vs ShA rats). B,
Responding (⫾SE) during the final self-administration session (represented as the 2 h mean in LgA rats) and the 10 consecutive 2 h
extinctions sessions is shown. Significant differences in extinction responding between ShA and LgA rats were not found. C,
Significant intra-VTA CRF-induced reinstatement was observed in LgA but not ShA rats, and CRF-induced responding was significantly higher in LgA rats compared with ShA rats and Sal controls at both doses tested (*p ⬍ 0.05), and increased compared with
vehicle at the 500 ng/side (but not the 250 ng/side) CRF dose ( #p ⬍ 0.05). D, Effects on responding on the previously inactive lever
during reinstatement testing were not found.

following intra-VTA delivery of either 250 ng/side CRF (one-way
ANOVA, F(2,19) ⫽ 4.179, p ⬍ 0.05; significant increase in LgA vs
either ShA or Sal, p ⬍ 0.05, Bonferroni-corrected t test) or 500
ng/side CRF (one-way ANOVA, F(2,19) ⫽ 23.103, p ⬍ 0.001; significant increase in LgA vs either ShA or Sal, p ⬍ 0.05). By contrast, we failed to find reinstatement effects or self-administration
group effects on responding on the previously inactive lever or a
reinstatement ⫻ group interaction (Fig. 2 D).
Effects of intra-VTA CRF-R1 antagonists on CRF-induced
reinstatement
Bilateral intra-VTA pretreatment with the CRF-R1-selective antagonist antalarmin or CP-376395 blocked reinstatement by intra-VTA
CRF (500 ng/side) in LgA rats (Fig. 3). The effect of antalarmin on
CRF-induced reinstatement (n ⫽ 7) is shown in Figure 3A, and the
effect of CP-376395 on CRF-induced reinstatement (n ⫽ 6) is shown
in Figure 3B. In both cases, two-way repeated measures (CRF vs
extinction; antagonist vs vehicle) ANOVA showed significant main
effects of CRF delivery (F(1,6) ⫽ 12.603, p ⬍ 0.05 for antalarmin;
F(1,5) ⫽ 6.920, p ⬍ 0.05 for CP-376395), but not antagonist treat-

Effects of intra-VTA CRF-R1
antagonism on stress-induced
reinstatement
Antagonism of CRF-R1 in the VTA also
blocked footshock-induced reinstatement
in LgA rats (n ⫽ 6) (Fig. 3C). Two-way
(footshock vs extinction; antalarmin vs vehicle) repeated-measures ANOVA showed
a significant overall effect of footshock
(F(1,5) ⫽ 28.817, p ⬍ 0.01), but not antalarmin pretreatment, and a significant antalarmin ⫻ footshock interaction (F(1,5) ⫽
6.294, p ⫽ 0.05). Intra-VTA CRF produced
significant reinstatement following pretreatment with vehicle (p ⬍ 0.01), but not
antalarmin, and responding following EFS
was significantly lower following antalarmin pretreatment compared with vehicle
pretreatment (p ⬍ 0.01).

Effects of intra-VTA CRF-R1
antagonists on food-reinforced
lever pressing
To confirm that the effects of intra-VTA
antalarmin and CP-376395 on reinstatement were not attributable to nonspecific
motor impairments, effects on sucrose
pellet-reinforced lever pressing were examined. Neither intra-VTA antalarmin
(185.83 ⫾ 28.86 responses/30 min session vs 211.80 ⫾ 13.41 responses/session for vehicle) nor intra-VTA CP-376395 (192.67 ⫾
23.73 responses/30 min session vs 203.10 ⫾ 13.17 responses/session
for vehicle) significantly decreased food-reinforced responding at
doses that blocked CRF- or footshock-induced reinstatement. When
interpreting these findings, it is important to note that in contrast to
our self-administration rats, these rats had no history of cocaine
intake and were food restricted, possibly altering their sensitivity to
CRF-R1 antagonism.
Effects of intra-VTA CRF-R2 antagonists on CRF- and
stress-induced reinstatement
The effects of bilateral intra-VTA pretreatment with CRF-R2selective antagonists astressin-2B or ASV-30 on reinstatement by
intra-VTA CRF (500 ng/side) are shown in Figure 4, A and B. The
effects of the astressin-2B on CRF-induced reinstatement (n ⫽ 6)
are shown in Figure 4 A. We initially tested rats for the effect of
astressin-2B at the 500 ng/side astressin-2B dose. However, since
this dose of astressin-2B did not attenuate reinstatement, we also
tested rats with a twofold higher dose of astressin-2B (1 g/side).
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Two-way repeated-measures ANOVA examining the effects of both astressin-2B
doses on reinstatement showed a significant overall effect of CRF-induced reinstatement (F(1,5) ⫽ 52.077, p ⫽ 0.001), but
not astressin-2B pretreatment, and no significant astressin-2B ⫻ CRF reinstatement interaction. Significant intra-VTA
CRF-induced reinstatement was observed
in rats pretreated with vehicle or either
astressin-2B dose (p ⬍ 0.01 for each comparison), and reinstatement was not significantly different following astressin-2B
delivery when compared with vehicle administration. Likewise, intra-VTA pretreatment with ASV-30 failed to alter
reinstatement by intra-VTA CRF (n ⫽ 6)
(Fig. 4 B). Two-way repeated-measures
ANOVA showed a significant overall effect of CRF-induced reinstatement (F(1,5)
⫽ 8.462, p ⬍ 0.05), but not ASV-30 pretreatment, and no significant ASV-30 ⫻
CRF reinstatement interaction. Significant intra-VTA CRF-induced reinstatement was observed in rats pretreated with
vehicle or ASV-30 (p ⬍ 0.01), and reinstatement was not different following
ASV-30 delivery when compared with vehicle administration.

Figure 3. Effects of intra-VTA injections of CRF-R1 antagonists on reinstatement by intra-VTA CRF delivery and footshock stress
in LgA rats. A, B, Data represent the effects of bilateral injections of antalarmin (A, 500 ng/side; n ⫽ 7), CP-376395 (B, 500 ng/side;
n ⫽ 6), or vehicle on reinstatement by bilateral intra-VTA delivery of CRF (500 ng/side) and the effects of bilateral injections of
antalarmin (500 ng/side) on reinstatement (responses/2 h session ⫾ SE) by electric footshock (C, n ⫽ 6). In all cases, significant
reinstatement was observed in rats pretreated with vehicle [*p ⬍ 0.05 vs extinction (Ext)] but not CRF-R1 antagonists, and
responding during reinstatement was significantly lower following administration of CRF-R1 antagonists compared with vehicle
( #p ⬍ 0.05 vs Veh).

Effects of intra-VTA CRF-R2
antagonism on stress-induced
reinstatement
Intra-VTA pretreatment with the CRFR2-selective antagonist astressin-2B also
failed to alter footshock-induced reinstatement (n ⫽ 8) (Fig. 4C). As was the case
with CRF-induced reinstatement, ANOVA Figure 4. Effects of intra-VTA injections of CRF-R2 antagonists on reinstatement by intra-VTA CRF delivery and footshock stress
showed a significant overall effect of foot- in LgA rats. A, B, Data represent the effects of bilateral injections of astressin-2B (A, 500 ng and 1 g/side; n ⫽ 6), ASV-30 (B, 500
shock reinstatement (F(1,7) ⫽ 20.587, p ⬍ ng/side; n ⫽ 6), or vehicle on reinstatement by bilateral intra-VTA delivery of CRF (500 ng/side) and the effects of bilateral
0.01), but not astressin-2B pretreatment, injections of astressin-2B (500 ng/side) on reinstatement (responses/2 h session ⫾ SE) by electric footshock (C, n ⫽ 8). In all cases,
and no significant interaction. Significant significant reinstatement was observed in rats pretreated with vehicle or CRF-R2 antagonists [*p ⬍ 0.05 vs extinction (Ext)], while
footshock-induced reinstatement was ob- CRF-R2 antagonist pretreatments failed to attenuate reinstatement by intra-VTA CRF or shock.
served in rats pretreated with vehicle or
ment or reinstatement testing or a rUCN II ⫻ reinstatement
astressin-2B (p ⬍ 0.01), and reinstatement was not different followtesting interaction. Intra-VTA cortagine treatment increased reing astressin-2B delivery when compared with vehicle.
sponding compared with the preceding extinction session (p ⬍
0.05) and with vehicle-treated rats (p ⬍ 0.05).
Reinstatement by intra-VTA administration of the CRF
receptor agonists
To further examine the role of VTA CRF-R1 and CRF-R2 in
reinstatement, the ability of bilateral intra-VTA injection of the
selective CRF-R1 agonist cortagine (100 ng/side) or the selective
CRF-R2 agonist rUCN II (250 ng/side) to reinstate cocaine seeking was examined in a separate group of LgA rats (n ⫽ 5) (Fig. 5).
Reinstatement was observed following intra-VTA delivery of cortagine but not rUCN II. A two-way repeated-measures ANOVA
with reinstatement condition (extinction vs intra-VTA treatment) and drug treatment (cortagine vs vehicle) as factors
showed a significant overall main effect of reinstatement (F(1,4) ⫽
17.316, p ⬍ 0.05), but not cortagine treatment, and a significant
reinstatement ⫻ cortagine treatment interaction (F(1,4) ⫽ 7.626,
p ⫽ 0.05). By contrast, an identical analysis examining rUCN
II-induced reinstatement failed to show effects of rUCN II treat-

Discussion
We have reported that self-administration under LgA/highintake conditions augments later reinstatement by footshock
stress and intracerebroventricular CRF (Mantsch et al., 2008),
and that footshock-induced reinstatement following LgA
self-administration is CRF dependent (Graf et al., 2011). These
findings are consistent with prior reports that stress-induced reinstatement of drug seeking following self-administration of cocaine (Erb et al., 1998), heroin (Shaham et al., 1997), alcohol (Lê
et al., 2000), or nicotine (Bruijnzeel et al., 2009) involves CRF, as
does stress-induced reinstatement of palatable food-seeking behavior (Ghitza et al., 2006). Our current findings demonstrate
that heightened CRF responsiveness in the VTA likely contributes to intake-dependent increases in vulnerability to stress-

Blacktop et al. • VTA CRF-R1s and Cocaine Addiction

Figure 5. Reinstatement by intra-VTA administration of the CRF-R1-selective agonist cortagine and the CRF-R2-selective agonist rUCN II in LgA rats (n ⫽ 5). Cortagine (100 ng/side), but
not UCN II (250 ng/side) or vehicle, reinstated extinguished cocaine seeking (*p ⬍ 0.05 vs
vehicle and the preceding extinction session). The data represent responding on the cocaine
lever (responses/2 h session ⫾ SE) during extinction or following bilateral intra-VTA cortagine
or Veh treatment.

induced relapse that emerge with repeated drug use. Previous
studies have reported that VTA CRF levels are increased during
stress-induced reinstatement and that stress-induced cocaine
seeking involves CRF actions in the VTA (Wang et al., 2005,
2007). Here we report that, similar to stress-induced reinstatement, reinstatement by intra-VTA CRF was augmented, and
in fact was only observed, in rats with a history of selfadministration under LgA/high-intake conditions. Further, we
find that cocaine seeking induced by CRF delivery into the VTA
or by footshock is mediated by VTA CRF-R1 and not CRF-R2, a
finding that contrasts with previous reports implicating CRF-R2
in the VTA in stress-induced reinstatement (Wang et al., 2005,
2007).
A circuit involving the regulation of VTA dopaminergic neurons that project to the dorsal medial prefrontal cortex has been
implicated in stress-induced relapse (McFarland et al., 2004).
According to this model, inputs from several regions, including
the ventral bed nucleus of the stria terminalis (vBNST), the central nucleus of the amygdala (CeA), and the NAc shell positively
regulate mesocortical dopamine neurons in the VTA, thereby
promoting cocaine seeking through activation of corticostriatal
glutamatergic inputs into the NAc core. It has been reported that
the VTA receives CRF-containing afferents from two of these
regions, the CeA and vBNST (Rodaros et al., 2007), and dual
immunolabeling studies indicate that these CRF-containing projections are primarily glutamatergic (Tagliaferro and Morales,
2008). CRF-containing afferents form synapses on dopaminergic
and GABAergic cells in the VTA (Tagliaferro and Morales, 2008),
and the activity of both cell types is altered upon local CRF application (Korotkova et al., 2006). In the case of dopaminergic cells,
CRF-positive synapses are primarily asymmetric (Tagliaferro and
Morales, 2008), suggesting that CRF-releasing glutamatergic
projections into the VTA, likely originating in the vBNST and
CeA, positively regulate the activity of dopaminergic cells. Accordingly, delivery of CRF into the VTA stimulates local and
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terminal field dopamine release (Kalivas et al., 1987; Wang et al.,
2005).
Although CRF-R1s are abundant in the VTA, their expression
on dopaminergic cells appears to be somewhat limited (Korotkova et al., 2006), suggesting that actions of CRF on nondopaminergic cells may contribute to its effects on cocaine seeking.
GABAergic cells in the VTA have also been reported to express
CRF-R1s (Korotkova et al., 2006). The pattern of expression on
other cell types in the VTA (glial cells, glutamatergic neurons) is
unknown. The picture is less clear for CRF-R2s. Despite pharmacological evidence for CRF-R2 expression in the VTA (Wang et
al., 2007), examination of the VTA using in situ hybridization
suggests that there is little or no cell body expression (Van Pett et
al., 2000). However, CRF-R2 expression has been reported as
determined by RT-PCR (Korotkova et al., 2006). The purported
ability of CRF-R2s to locally regulate glutamate release suggests a
potential presynaptic localization of CRF-R2s on glutamate terminals (Wang et al., 2007). A clear understanding of the localization of CRF-R2s in the VTA awaits the availability of better
antibodies for immunohistochemical characterization.
The precise mechanism of CRF regulation of dopaminergic
cells in the VTA is also unclear and has been reported to involve
both CRF-R1-mediated activation of protein kinase C (PKC)
(Wanat et al., 2008) and possibly PKA (Riegel and Williams,
2008) signaling and/or CRF-R2 facilitation of NMDA receptor
function (Ungless et al., 2003). The CRF-R2 effects on signaling
also appear to require CRF interaction with CRF binding protein
(Ungless et al., 2003; Wang et al., 2005) and may also involve
presynaptic enhancement of glutamate release (Wang et al., 2005,
2007).
While our data implicate CRF actions in the VTA in stressinduced reinstatement, others have reported that CRF can act
elsewhere within this circuit, including at sites upstream from the
VTA, to regulate cocaine seeking, most notably in the vBNST,
where CRF receptor antagonism blocks stress-induced cocaine
seeking (Erb and Stewart, 1999). As the CRF actions in the vBNST
involve projections from the CeA (Erb et al., 2001) and both
regions send CRF-containing efferents to the VTA (Rodaros et
al., 2007), it is likely that CRF exerts actions at multiple sites in the
circuit that contribute to stress-induced cocaine seeking.
Similar to what we previously reported with stress-induced
reinstatement (Mantsch et al., 2008), reinstatement by intra-VTA
CRF appeared to represent an emergent phenomenon in that it
was only observed following LgA self-administration. This finding is consistent with a report by Wang et al. (2005), who found
that while footshock-induced increases in VTA CRF were observed in the VTA, the ability of CRF to regulate dopamine and
glutamate levels in the VTA required a history of cocaine selfadministration. The apparent augmentation of CRF responsiveness is also consistent with reports that CRF responsiveness in a
number of brain regions is heightened following repeated cocaine
administration (Erb et al., 2005; Liu et al., 2005; Pollandt et al.,
2006; Orozco-Cabal et al., 2008; Francesconi et al., 2009; Guan et
al., 2009). Although the effects of LgA cocaine self-administration on CRF-R1-mediated actions in the VTA have not been
examined, some insight into potential mechanisms underlying
heightened CRF regulation of cocaine seeking can be provided by
studies involving repeated experimenter-delivered cocaine. In
the VTA, CRF-R1 activation has been reported to produce both
excitatory effects (via potentiation of NMDA and AMPA
receptor-mediated neurotransmission) (Hahn et al., 2009) and
inhibitory effects (via enhancement of D2 dopamine- and
GABAB-receptor mediated regulation of G-protein-activated in-
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wardly rectifying potassium channels) (Beckstead et al., 2009) on
dopaminergic neurons. With repeated cocaine exposure, the excitatory effects of CRF-R1 activation are augmented (Hahn et al.,
2009), while the inhibitory effects diminish (Beckstead et al.,
2009), likely resulting in a net shift toward positive CRF-R1 regulation of dopaminergic cells in the VTA. Further, CRF binding
in the VTA, as measured using autoradiography, is increased with
repeated cocaine delivery (Goeders et al., 1990).
Our findings that VTA CRF-R1s mediate CRF- and stressinduced cocaine seeking are inconsistent with previous reports suggesting involvement of CRF-R2s in the VTA, apparently through a
mechanism that also involves CRF binding protein (Wang et al.,
2005, 2007). However, others have reported that stress-induced reinstatement is inhibited by systemic or intracerebroventricular delivery of CRF-R1, but not CRF-R2, antagonists (Shaham et al., 1998;
Lu et al., 2001) and that CRF-R1, but not CRF-R2, antagonism can
reduce evoked increases in VTA and NAc dopamine (Lu et al., 2003;
Lodge and Grace, 2005). The reason for the discrepancy between our
findings and those of Wang et al. (2005, 2007) is unclear but may
involve different modes of CRF and receptor antagonist delivery
(microinjection vs reverse dialysis), different CRF receptor antagonist and agonist doses, different rat strains, and differential experimental histories. Most importantly, it may be that the regulation of
cocaine seeking by CRF-R1 in VTA requires a history of very high
levels of cocaine intake [the daily cocaine intake reported by Wang et
al. (2005, 2007) was ⬃33 mg/kg compared with ⬎70 mg/kg in our
LgA rats], which is consistent with reports that the selective
CRF-R1 antagonists antalarmin and N,N-bis(2-methoxyethyl)-3(4-methoxy-2-methylphenyl)-2,5-dimethyl-pyrazolo[1,5a]pyrimidin-7-amine (MPZP) only reduce cocaine self-administration
following escalation in LgA rats (Specio et al., 2008).
The ability of stressful life events to precipitate drug use
through actions involving CRF-R1s in the VTA may represent
an emergent consequence of excessive cocaine use. Identification of the precise mechanisms through which VTA CRF-R1
activation produces cocaine seeking and the neuroadaptations
that contribute to heightened susceptibility to CRF-dependent reinstatement should provide important insight into how stressor responsiveness changes in cocaine addicts in a way that promotes
further use.
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